Company environment · IVD & medical devices · FDA CDRH
NGS companion diagnostic PMA submission
PMA dossier sections being finalized for FDA CDRH submission.
1What does this company do?
In vitro diagnostics manufacturer preparing an FDA CDRH Premarket Approval (PMA) submission for a tumor-profiling NGS assay.
2Where is the product on its way to patients?
Multi-biomarker NGS companion diagnostic (CDx) at pre-submission PMA lock.
- 1Discovery & Lead Selection
- 2IND-Enabling Nonclinical
- 3Clinical Development (IND / CTA)
- 4Registration & Dossier Review
- The product is here
- 5Approval & Launch Readiness
- 6Commercial Lifecycle & GMP
3What is happening right now?
The PMA submission locks on the 6th, with six technical and labeling sections awaiting cross-functional sign-off.
4Tasks
6 tasks in the 81-task Biopharma Bench V0.2 suite, graded against expert rubric criteria.
Sealed partner records & open showcases
This environment is reconstructed from a confidential drug or device program, so its records, tasks, and rubrics remain sealed.
To inspect complete workspaces, candidate deliverables, trajectories, and rubric criteria end to end, open the two public companion showcases:
Havenor Therapeutics (synthetic sterile-injectables CMC/MSAT) →
Broad Institute (public FDA CDER IND 167326 record) →